Alpha-GPC ื”ืจื›ื™ื‘ ืฉืžื—ืงืจื™ื ื’ื™ืœื• ืฉืžืฉืคืจ ืจื™ื›ื•ื– ื•ื–ื™ื›ืจื•ืŸ

Alpha-GPC ื”ื•ื ืžืงื•ืจ ื›ื•ืœื™ืŸ ื”ืžืกื™ื™ืข ืœื™ื™ืฆื•ืจ ืืฆื˜ื™ืœื›ื•ืœื™ืŸ ื‘ืžื•ื—. ื’ืœื” ืžื” ื”ืžื—ืงืจ ื”ืžื“ืขื™ ืื•ืžืจ ืขืœ ื”ื™ืชืจื•ื ื•ืช ื”ืงื•ื’ื ื™ื˜ื™ื‘ื™ื™ื ืฉืœื• ื•ืื™ืš ื”ื•ื ืคื•ืขืœ.

Alpha-GPC ื”ืจื›ื™ื‘ ืฉืžื—ืงืจื™ื ื’ื™ืœื• ืฉืžืฉืคืจ ืจื™ื›ื•ื– ื•ื–ื™ื›ืจื•ืŸ

ื‘ื™ืŸ ื›ืœ ื”ืจื›ื™ื‘ื™ื ื”ื ื•ื˜ืจื•ืคื™ื™ื ืฉื ื—ืงืจื• ื‘ืฉื ื™ื ื”ืื—ืจื•ื ื•ืช, Alpha-GPC ื‘ื•ืœื˜ ื‘ืžื™ื•ื—ื“. ืœื ื‘ื’ืœืœ ืฉื™ื•ื•ืงย  ื‘ื’ืœืœ ืžื“ืข. ืžื“ื•ื‘ืจ ื‘ืจื›ื™ื‘ ืฉืžืชืงื™ื™ืžื™ื ืขืœื™ื• ืขืฉืจื•ืช ืžื—ืงืจื™ื ืงืœื™ื ื™ื™ื, ืฉื ื‘ื—ืŸ ื‘ื‘ืชื™ ื—ื•ืœื™ื ื•ืื•ื ื™ื‘ืจืกื™ื˜ืื•ืช, ื•ืฉื”ื•ืคื™ืข ื™ื•ืชืจ ื•ื™ื•ืชืจ ื‘ื ื•ืกื—ืื•ืช ืชื•ืกืคื™ ืชื–ื•ื ื” ืžื•ื‘ื™ืœื™ื ื‘ืจื—ื‘ื™ ื”ืขื•ืœื.

ืžื” ื–ื” Alpha-GPC?

Alpha-GPC (Alpha-glycerophosphocholine) ื”ื•ื ืชืจื›ื•ื‘ืช ื›ื•ืœื™ืŸ ื‘ืขืœืช ื–ืžื™ื ื•ืช ื‘ื™ื•ืœื•ื’ื™ืช ื’ื‘ื•ื”ื” ื‘ืžื™ื•ื—ื“. ื›ื•ืœื™ืŸ ื”ื•ื ื ื•ื˜ืจื™ื™ื ื˜ ื—ื™ื•ื ื™ ื”ืžื•ื— ืฉืœืš ืžืฉืชืžืฉ ื‘ื• ื›ื“ื™ ืœื™ื™ืฆืจ ืืฆื˜ื™ืœื›ื•ืœื™ืŸ, ื”ื ื•ื™ืจื•ื˜ืจื ืกืžื™ื˜ืจ ื”ืžืจื›ื–ื™ ื”ืื—ืจืื™ ืขืœ ืœืžื™ื“ื”, ื–ื™ื›ืจื•ืŸ ื•ืชื™ืื•ื ืขืฆื‘-ืฉืจื™ืจ.

ื‘ื ื™ื’ื•ื“ ืœืฆื•ืจื•ืช ื›ื•ืœื™ืŸ ืื—ืจื•ืช (ื›ืžื• ื›ื•ืœื™ืŸ ื‘ื™ื˜ืจื˜ืจื˜), Alpha-GPC ื—ื•ืฆื” ืืช ืžื—ืกื•ื ื“ื-ืžื•ื— ื‘ืงืœื•ืช ื™ื—ืกื™ืช, ืžื” ืฉืื•ืžืจ ืฉื›ืžื•ืช ื’ื“ื•ืœื” ื™ื•ืชืจ ืžืžื” ืฉืืชื” ืœื•ืงื— ืื›ืŸ ืžื’ื™ืขื” ืœื™ืขื“ื” ื”ืžื•ื—.

ื”ืžื ื’ื ื•ืŸ: ืื™ืš Alpha-GPC ืคื•ืขืœ ืขืœ ื”ืžื•ื—?

ื›ืฉAlpha-GPC ืžื’ื™ืข ืœืžื•ื—, ื”ื•ื ืžืชืคืจืง ืœื›ื•ืœื™ืŸ ื•ื’ืœื™ืฆืจื•ืคื•ืกืคื˜. ื”ื›ื•ืœื™ืŸ ืžืฉืžืฉ ื›ื—ื•ืžืจ ื’ืœื ืœืกื™ื ืชื–ื” ืฉืœ ืืฆื˜ื™ืœื›ื•ืœื™ืŸ.ย ืจืžื•ืช ื’ื‘ื•ื”ื•ืช ื™ื•ืชืจ ืฉืœ ืืฆื˜ื™ืœื›ื•ืœื™ืŸ ืงืฉื•ืจื•ืช ืœืชื”ืœื™ื›ื™ื ืงื•ื’ื ื™ื˜ื™ื‘ื™ื™ื ื›ืžื• ื–ื™ื›ืจื•ืŸ, ืงืฉื‘ ื•ืžื”ื™ืจื•ืช ืขื™ื‘ื•ื“ ืžื™ื“ืข, ื•ืœื›ืŸ ื—ื•ืงืจื™ื ื‘ื•ื—ื ื™ื ื”ืื ื”ืขืœืืช ื–ืžื™ื ื•ืช ื”ื›ื•ืœื™ืŸ ืขืฉื•ื™ื” ืœืชืžื•ืš ื‘ืชืคืงื•ื“ื™ื ืืœื”.

ืžื—ืงืจ ืฉืคื•ืจืกื ื‘ื›ืชื‘ ื”ืขืช Current Neuropharmacology (Traini et al., 2013, DOI: 10.2174/1871527311312010015) ื”ื“ื’ื™ื ืฉAlpha-GPC ืžืฉืคื™ืข ืขืœ ืžืขืจื›ืช ื”ืžื•ื ื•ืืžื™ื ืจื’ื™ืช ื‘ืžื•ื— โ€” ื›ื•ืœืœ ืขืœ ืฉื—ืจื•ืจ ื“ื•ืคืžื™ืŸ ื•ื ื•ืจืื“ืจื ืœื™ืŸ, ื ื•ื™ืจื•ื˜ืจื ืกืžื™ื˜ืจื™ื ื”ืงืฉื•ืจื™ื ืœืจื™ื›ื•ื– ื•ืœืžื•ื˜ื™ื‘ืฆื™ื”.

ืžื” ื”ืžื—ืงืจ ืื•ืžืจ?

ืกืงื™ืจื” ืฉืคื•ืจืกืžื” ื‘-Frontiers in Endocrinology ืžืฆื™ื™ื ืช ื›ื™ Alpha-GPC ื”ื•ื ืžืงื•ืจ ื›ื•ืœื™ืŸ ื‘ืขืœ ื–ืžื™ื ื•ืช ื‘ื™ื•ืœื•ื’ื™ืช ื’ื‘ื•ื”ื”, ื•ื›ื™ ื”ื•ื ื ื‘ื—ืŸ ื‘ืžืกืคืจ ื ื™ืกื•ื™ื™ื ืงืœื™ื ื™ื™ื ื‘ื”ืงืฉืจ ืฉืœ ืชืคืงื•ื“ ืงื•ื’ื ื™ื˜ื™ื‘ื™.

ืžื—ืงืจ ื ื•ืกืฃ ืฉืคื•ืจืกื ื‘-Nutrients (Lippelt et al., 2019, DOI: 10.3390/nu11122995) ื‘ื—ืŸ ืืช ื”ื”ืฉืคืขื•ืช ื”ื ื•ื™ืจื•ืคืจื•ื˜ืงื˜ื™ื‘ื™ื•ืช ืฉืœ ื›ื•ืœื™ืŸ ื•ืžืฆื ืฉืจืžื•ืช ื›ื•ืœื™ืŸ ืชืงื™ื ื•ืช ืงืฉื•ืจื•ืช ืœื‘ืจื™ืื•ืช ืขืฆื‘ื™ืช ื˜ื•ื‘ื” ื™ื•ืชืจ ื•ืœืกื™ื›ื•ืŸ ื ืžื•ืš ื™ื•ืชืจ ืœื™ืจื™ื“ื” ืงื•ื’ื ื™ื˜ื™ื‘ื™ืช.

ืžื™ื ื•ืŸ: ื›ืžื” Alpha-GPC ืฆืจื™ืš?

ื”ืžื™ื ื•ืŸ ืฉื ื—ืงืจ ื‘ื™ื•ืชืจ ื‘ืžื—ืงืจื™ื ืงืœื™ื ื™ื™ื ื ืข ื‘ื™ืŸ 300 ืœ-600 ืž"ื’ ืœื™ื•ื. ืžื—ืงืจื™ื ืขืœ ืฉื™ืคื•ืจ ืงื•ื’ื ื™ื˜ื™ื‘ื™ ื‘ื‘ื•ื’ืจื™ื ื‘ืจื™ืื™ื ื”ืฉืชืžืฉื• ืœืจื•ื‘ ื‘ืžื™ื ื•ื ื™ื ืฉืœ 300-400 ืž"ื’ ืœื™ื•ื, ื‘ื“ืจืš ื›ืœืœ ื›ืžื ื” ื™ื—ื™ื“ื” ื‘ื‘ื•ืงืจ.

ื—ืฉื•ื‘ ืœืฆื™ื™ืŸ ืฉืžื™ื ื•ืŸ ื’ื‘ื•ื” ืžื“ื™ (ืžืขืœ 1,200 ืž"ื’ ืœื™ื•ื) ืขืœื•ืœ ืœื’ืจื•ื ืœื›ืื‘ื™ ืจืืฉ ืืฆืœ ื—ืœืง ืžื”ืื ืฉื™ื โ€” ืžื” ืฉืžื“ื’ื™ืฉ ืืช ื”ื—ืฉื™ื‘ื•ืช ืฉืœ ื‘ื—ื™ืจืช ืชื•ืกืฃ ืฉืžืชื•ื›ื ืŸ ืขื ืžื™ื ื•ืŸ ืžืื•ื–ืŸ ื•ืžื‘ื•ืกืก ืขืœ ืขื“ื•ืช ืžื—ืงืจื™ืช.

Alpha-GPC ื‘-Think ืฉืœ Harmony

Think ืฉืœ Harmony ื›ื•ืœืœ Alpha-GPC ื‘ืžื™ื ื•ืŸ ืฉื ื‘ื—ืจ ืขืœ ื‘ืกื™ืก ื”ืกืคืจื•ืช ื”ืžื“ืขื™ืช. ื”ื•ื ืžื”ื•ื•ื” ืืช ืขืžื•ื“ ื”ืฉื“ืจื” ื”ืงื•ื’ื ื™ื˜ื™ื‘ื™ ืฉืœ ื”ื ื•ืกื—ื” โ€” ืžืกืคืง ืืช ื—ื•ืžืจ ื”ื’ืœื ื”ื ื“ืจืฉ ืœื™ื™ืฆื•ืจ ืืฆื˜ื™ืœื›ื•ืœื™ืŸ, ื‘ืฉื™ืœื•ื‘ ืขื ืจื›ื™ื‘ื™ื ืžืฉืœื™ืžื™ื ื›ืžื• Bacopa Monnieri ื•-sharpps ืฉืคื•ืขืœื™ื ื“ืจืš ืžื ื’ื ื•ื ื™ื ืฉื•ื ื™ื.

ืฉื™ืœื•ื‘ ื–ื” ืžื‘ื•ืกืก ืขืœ ืจื›ื™ื‘ื™ื ืฉื ื—ืงืจื• ื‘ื ืคืจื“ ื‘ื”ืงืฉืจื™ื ืฉื•ื ื™ื ืฉืœ ืชืคืงื•ื“ ืงื•ื’ื ื™ื˜ื™ื‘ื™.

ืœืžื™ Alpha-GPC ืžืชืื™ื?

  • ืกื˜ื•ื“ื ื˜ื™ื โ€” ื‘ืชืงื•ืคื•ืช ืฉืœ ืขื•ืžืก ืœื™ืžื•ื“ื™ ื’ื‘ื•ื”.
  • ืื ืฉื™ ืžืงืฆื•ืข โ€” ืฉืฆืจื™ื›ื™ื ืจื™ื›ื•ื– ืžืชืžืฉืš ืœืื•ืจืš ื™ื•ื ืขื‘ื•ื“ื” ืืจื•ืš.
  • ืกืคื•ืจื˜ืื™ื โ€” Alpha-GPC ื ื—ืงืจ ื’ื ื‘ื”ืงืฉืจ ืฉืœ ืชื™ืื•ื ืขืฆื‘-ืฉืจื™ืจ ื•ื™ื›ื•ืœืช ืกืคื•ืจื˜ื™ื‘ื™ืช.
  • ืžื‘ื•ื’ืจื™ื โ€” ืฉืžืขื•ื ื™ื™ื ื™ื ืœืชืžื•ืš ื‘ื‘ืจื™ืื•ืช ืงื•ื’ื ื™ื˜ื™ื‘ื™ืช ืœืื•ืจืš ื–ืžืŸ.

ื‘ื˜ื™ื—ื•ืช ื•ืฉื™ืงื•ืœื™ื ื—ืฉื•ื‘ื™ื

Alpha-GPC ื ื—ืฉื‘ ื‘ื˜ื•ื— ืœืฉื™ืžื•ืฉ ืœืคื™ ื”ืกืคืจื•ืช ื”ืžื“ืขื™ืช ื”ืงื™ื™ืžืช ื‘ื”ืชืื ืœืžื™ื ื•ื ื™ื ืฉื ื—ืงืจื•. ื”ื•ื ืžื•ืคื™ืข ื‘ืจืฉื™ืžืช GRAS (Generally Recognized As Safe) ื‘ืืจื”"ื‘. ื›ืžื• ื‘ื›ืœ ืชื•ืกืฃ, ืžื•ืžืœืฅ ืœื”ืชื™ื™ืขืฅ ืขื ืจื•ืคื ืื ืืชื ื ื•ื˜ืœื™ื ืชืจื•ืคื•ืช ืงื‘ื•ืขื•ืช.

ืจื•ืฆื™ื ืœื—ื•ื•ืช ืืช ื”ื›ื•ื— ืฉืœ Alpha-GPC ื‘ื ื•ืกื—ื” ืžืื•ื–ื ืช?

ื™ื—ื“ ืขื ืจื›ื™ื‘ื™ ื“ื’ืœ ื•ืขื ืจื›ื™ื‘ ื‘ืขืœ ืžืขืœ 50 ืžื—ืงืจื™ื ืงืœื™ื ื™ื.

ืœืจื›ื™ืฉืช Think ืœื—ืฅ ื›ืืŸ